Paper · 42909237

Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.

van der Waaij AM and 16 others. Theranostics, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer. Papers, record 42909237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909237

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.
Journal: Theranostics
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42909237/
DOI: https://doi.org/10.7150/thno.136523
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13684177/
The journal: https://conductscience.org/library/journal-index/101552395
Revised in PubMed: 2026-10-24

Source PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	van der Waaij AM	Anne M
2	van Ginkel YJ	Ymke J
3	Volkmer P	Pia
4	Kats-Ugurlu G	Gursah
5	Huizinga HK	Henrik K
6	Hone Lopez S	Sara
7	de Haan JJ	Jacco J
8	Bijlsma R	Rina
9	van der Waaij LA	Laurens A
10	Muijs CT	Christina T

1 to 10 of 17Source PubMed

See all 17 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal	Major topic
Esophageal Neoplasms	Major topic
B7-H1 Antigen	Major topic
Optical Imaging	Major topic
Antineoplastic Agents, Immunological	Major topic
Humans
Female
Male
Aged
Middle Aged

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	40,454,643	Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.	N Engl J Med	2025	https://conductscience.org/library/papers/40454643	PubMed
2	31,043,352	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.	Pathol Res Pract	2019	https://conductscience.org/library/papers/31043352	PubMed
3	25,364,580	Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review.	Cancer Biol Med	2014	https://conductscience.org/library/papers/25364580	PubMed
4	40,165,109	Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma.	BMC Cancer	2025	https://conductscience.org/library/papers/40165109	PubMed
5	32,540,465	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.	Biochim Biophys Acta Rev Cancer	2020	https://conductscience.org/library/papers/32540465	PubMed
6	35,800,186	Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.	World J Gastroenterol	2022	https://conductscience.org/library/papers/35800186	PubMed
7	32,226,534	Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.	Theranostics	2020	https://conductscience.org/library/papers/32226534	PubMed
8	26,623,522	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.	Eur J Cancer	2016	https://conductscience.org/library/papers/26623522	PubMed
9	39,911,244	Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.	EClinicalMedicine	2025	https://conductscience.org/library/papers/39911244	PubMed
10	40,513,524	Spatial heterogeneity of PD-L1 expression influence its assessment in esophageal squamous cell carcinoma.	Transl Oncol	2025	https://conductscience.org/library/papers/40513524	PubMed

1 to 10 of 42

See all 42 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42909237

GET https://conductscience.org/api/papers/v1/42909237/references?page=2

API reference For AI assistants